Novo’s Danish CEO Lars Fruergaard Jørgensen will face the U.S. Senate in September to defend Wegovy and Ozempic’s eye-watering prices. Read More
Novo’s Danish CEO Lars Fruergaard Jørgensen will face the U.S. Senate in September to defend Wegovy and Ozempic’s eye-watering prices. Read More